Clinical Laboratory Molecular Diagnostics Test using inVivoScribe reagents kit.

SOL #: 75N98026Q00654Pre-Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH OLAO
BETHESDA, MD, 20892, United States

Place of Performance

Bethesda, MD

NAICS

All Other Professional (541990)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Jun 17, 2026
2
Response Deadline
Jun 29, 2026, 1:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institutes of Health (NIH), specifically the Office of Acquisition and Logistics Management, has issued a Presolicitation Non-Competitive (Notice of Intent) to award a contract for Clinical Laboratory Molecular Diagnostics Tests using inVivoScribe reagents kit. The NIH intends to award this contract to Invivoscribe, Inc. without full and open competition. Interested parties capable of fulfilling this requirement must submit their capabilities by June 29, 2026, at 9:00 AM Eastern time.

Scope of Work

The requirement is for molecular diagnostics tests and reagents to support the Molecular Diagnostics Laboratory of the Laboratory of Pathology. This laboratory performs molecular testing for cancer diagnosis, prognosis, and identifying targets for personalized therapies. Key components include:

  • InvivoScribe IgH +IgK B-cell clonality Assays: Used for identifying clonal immunoglobulin heavy chain and kappa light chain gene rearrangement, crucial for detecting B-cell malignancies, determining lineage of leukemias and lymphomas, and monitoring disease recurrence.
  • Specimen Size Control Ladder: Essential for identifying amplifiable fragmented DNA and determining the quality of patient DNA samples.

Contract & Timeline

  • Type: Presolicitation Non-Competitive (Notice of Intent) to award a contract or purchase order.
  • Intended Awardee: Invivoscribe, Inc.
  • Set-Aside: N/A
  • NAICS Code: 541990 (All Other Professional, Scientific, and Technical Services) with a Size Standard of $19,500,000.
  • Product/Service Code: 6505 (Drugs And Biologicals).
  • Authority: FAR Subpart 13-Simplified Acquisition Procedures, specifically 13.106-1(b)(1) for soliciting from a single source, not exceeding the simplified acquisition threshold ($350,000).
  • Published Date: June 17, 2026
  • Response Due: June 29, 2026, 9:00 AM Eastern time

Evaluation

This is not a request for competitive proposals. However, the Government will consider capability statements from other responsible sources to determine if a competitive procurement is feasible. A decision not to compete is solely at the Government's discretion.

Additional Notes

Responses must include a technical proposal, cost-price proposal, period of performance, Unique Entity ID (UEI), Taxpayer Identification Number (TIN), and certification of business size. All offerors must have an active registration in SAM.gov. Submissions must reference solicitation number 75N98026Q00654 and be sent electronically to James.Law@nih.gov. Fax responses will not be accepted.

People

Points of Contact

LAW, JAMES BPRIMARY

Files

Files

No files attached to this opportunity

Versions

Version 1Viewing
Pre-Solicitation
Posted: Jun 17, 2026
Clinical Laboratory Molecular Diagnostics Test using inVivoScribe reagents kit. | GovScope